Study: IVF Pregnancy Rates Soar after Massage
09 juil. 2019 08h00 HE
|
Clear Passage Therapies
Gainesville, FL, July 09, 2019 (GLOBE NEWSWIRE) -- Researchers and physicians were surprised that IVF pregnancy rates increased three to five times the U.S. norm in women over 40 when they...
ObsEva Progressing Toward U.S. Phase 3 Trial for Nolasiban in IVF Following Recent FDA Meeting
19 juin 2019 01h00 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA – June 19, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Announces Completion of Patient Recruitment in IMPLANT 4 Phase 3 Clinical Trial of Nolasiban for Improving IVF Outcomes
04 juin 2019 01h00 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA – June 4, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF
29 avr. 2019 01h00 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva R&D Day Showcases Multiple Women’s Health Programs and Outlines Plans for Transition to Commercial Operations
07 déc. 2018 12h12 HE
|
ObsEva SA
Clinical Trial Data and Regulatory Progress on Lead Programs Targeting IVF, Endometriosis, and Uterine Fibroids to Transform Company in 2019 GENEVA, Switzerland and BOSTON, Mass. (December...
ObsEva SA Announces Initiation of Phase 3 IMPLANT 4 Trial of Nolasiban in Europe, Canada and Russia for Improving IVF Outcomes
28 nov. 2018 01h00 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA – November 28, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
09 oct. 2018 16h15 HE
|
ObsEva SA
Abstract featuring-IMPLANT2 data awarded Prize Paper by Society for Assisted Reproductive Technology (SART) Nolasiban treatment shown to significantly increase Live Birth Rate (LBR) in...
ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results of Nolasiban in IVF to be Presented at Annual ASRM Meeting Tuesday October 9, 2018
05 oct. 2018 01h00 HE
|
ObsEva SA
Recipient of Prize Paper Award from the Society for Assisted Reproductive Technology (SART) Geneva, Switzerland and Boston, MA - October 5, 2018- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a...
ObsEva SA reports additional positive Phase 3 results of IMPLANT 2 trial showing significant increase of Live Birth Rate (LBR) following IVF with Single Embryo Transfer (SET)
03 oct. 2018 01h00 HE
|
ObsEva SA
Phase 3 IMPLANT 2 trial results showed Live Birth Rate increased by up to 35% with Nolasiban treatment Nolasiban safety profile not different from placebo in IMPLANT 2 European MAA submission...
Taconic Biosciences Launches ExpressMODEL™, a New Accelerated Model Generation Service
03 avr. 2017 10h30 HE
|
Taconic Biosciences
HUDSON, N.Y., April 03, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, has launched ExpressMODEL™, an innovative and...